Introduction: Malignant breast neoplasm is one of the leading causes of female mortality in Brazil and represents a significant public health challenge. Early detection and appropriate treatment are fundamental for reducing mortality; however, despite advances in diagnosis and therapy, breast cancer death rates continue to rise. In the Brazilian context, the disease affects different regions of the country unequally, particularly less developed areas such as the Northern Region, where access to specialized care is more limited. Therefore, it is crucial to analyze the temporal trend of breast cancer mortality rates in Brazil between 2009 and 2021, in order to identify patterns and guide interventions that could mitigate the impact of this condition. Objectives: To analyze the temporal trend and projections of mortality from malignant breast neoplasms in Brazil between 2009 and 2021. Methods: This is a cross-sectional, observational, and retrospective study that utilized secondary data from DATASUS. The number of deaths was used to calculate mortality rates. Temporal analysis methods and Prais-Winsten regression were applied to identify trends, with mortality rates calculated by age group and region. The annual percent change (APC) and its 95% confidence intervals were determined, categorizing the trends as increasing, decreasing, or stable. Results: During the period from 2009 to 2021, a total of 172,750 deaths from malignant breast neoplasms were recorded in Brazil among individuals aged 20 to 79 years, with 92,343 deaths (53.40%) occurring in the 50 to 69-year age group. Of this total, the Northern Region accounted for 7,290 deaths (4.22%), with 3,620 deaths (49.65%) occurring in individuals aged 50 to 69 years. Temporal analysis demonstrated an overall increasing trend in both Brazil and the Northern Region, with different variations across the analyzed age groups. The Annual Percent Change (APC) in the 20 to 79-year age group was 45.8% (95% CI: 50.53–41.08) in Brazil and 52.99% (95% CI: 60.03–45.94) in the Northern Region. In the 50 to 69-year age group, the APC was 28.77% (95% CI: 37.16–20.4) in Brazil, while in the Northern Region it reached 124.51% (95% CI: 141.72–107.31). Conclusion: The data reveal an increasing trend in mortality from malignant breast neoplasms in Brazil, particularly among individuals aged 50 to 69 years and in the Northern Region, which showed a significant rise in rates. This scenario highlights the urgent need to improve access to healthcare services, focusing on prevention and early diagnosis, especially in regions with less developed infrastructure. The highlighted annual percent change underscores the persistence of regional inequalities in the control of this disease, emphasizing the importance of public policies aimed at expanding screening and providing equitable and appropriate treatment across the country.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
